US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,565.03

+29.621.93%

Number of Gainers:2

Number of Losers:- -

Number of Flat:- -

PE:- -

High:1,576.53

Open:1,538.50

Low:1,538.50

Close:1,535.40

Volume:17.17M

Turnover:2.11B

Market Cap:406.81B

Float Cap:394.40B

Loading ...

Nyse Order Imbalance 90059.0 Shares on Sell Side

THOMSON REUTERS

BUZZ-RBC Capital Markets says Gilead's Yeztugo sales to beat Q3 estimates; shares up

Gilead Sciences Shares Hit All Time High; Last up 4.7%

THOMSON REUTERS

Novartis Says 5-Year Kisqali Data Cut Early Breast Cancer Recurrence by 28%

MT Newswires Live

Novartis Says European Regulator Backs Expanded Use of Blood Cancer Drug

MT Newswires Live

Novartis Scemblix receives positive CHMP opinion for Scemblix

Gilead Sciences Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares

Novartis' Phase 3 Study of Fabhalta in IgA Nephropathy Meets Primary Endpoint

MT Newswires Live

Novartis announces Phase III study of Fabhalta showed superiority to placebo

Gilead presents new HIV research data at European AIDS Conference

Novartis Growth Should Normalize After Successful Turnaround -- Market Talk

Gilead Sciences Announces Positive Phase 2 Results for Twice-Yearly Lenacapavir and Advances Long-Acting HIV Prevention and Treatment at EACS 2025

Gilead Presents New Hiv Research Data at Eacs 2025 – Driving Scientific Innovation in Treatment and Prevention

THOMSON REUTERS

Gilead Announces Promising Phase 3 Results for Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer and New Data on Domvanalimab Combination in Gastric and Esophageal Cancer

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at Esmo 2025

THOMSON REUTERS

Novartis Growth Likely to Stall on Cosentyx Sales Slide -- Market Talk

Press Release: Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Gilead : Citigroup Raises Target Price to $135 From $125

THOMSON REUTERS

Gilead price target raised to $135 from $125 at Citi

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Veeva Systems (VEEV)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1565.0261,"timestamp":1760731199999,"preClose":1535.4019,"halted":0,"volume":17171615,"delay":0,"changeRate":0.019294,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":29.624268,"latestTime":"10-17 16:00:00 EDT","open":1538.4999,"high":1576.5337,"low":1538.4999,"amount":2114065436.749296,"amplitude":0.024771,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.485206,"peRate":20.028615,"turnoverRate":0.005571,"increases":2,"decrements":0,"flats":0,"marketCap":406812655616,"floatMarketCap":394400251904},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1576.5337,"amplitude":0.024771,"preClose":1535.4019,"low":1538.4999,"pbRate":"6.485206","latestPrice":1565.0261,"volume":17171615,"delay":0,"open":1538.4999,"prevYearClose":1164.883,"prevWeekClose":1527.2168,"prevMonthClose":1484.4005,"prevQuarterClose":1484.4005,"fiveDayClose":1527.2168,"twentyDayClose":1459.6134,"sixtyDayClose":1414.3706,"secType":"PLATE","market":"US","turnoverRate":0.005571,"peRate":20.028615,"marketCap":406812655616,"floatMarketCap":394400251904,"timestamp":1760731199999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576758066","title":"Nyse Order Imbalance  90059.0 Shares on Sell Side","url":"https://stock-news.laohu8.com/highlight/detail?id=2576758066","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576758066?lang=en_us&edition=fundamental","pubTime":"2025-10-18 03:50","pubTimestamp":1760730602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nAQN2L3QWH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0208291251.USD","IE00BJT1NW94.SGD","NVS","BK4007","IE00B2B36J28.USD","LU0070302665.USD","LU0320765489.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4588","BK4578","IE00BJJMRZ35.SGD","BK4532","BK4585","IE00B4R5TH58.HKD","LU0211331839.USD"],"gpt_icon":0},{"id":"2576068557","title":"BUZZ-RBC Capital Markets says Gilead's Yeztugo sales to beat Q3 estimates; shares up","url":"https://stock-news.laohu8.com/highlight/detail?id=2576068557","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576068557?lang=en_us&edition=fundamental","pubTime":"2025-10-18 01:30","pubTimestamp":1760722216,"startTime":"0","endTime":"0","summary":"BUZZ-RBC Capital Markets says Gilead's Yeztugo sales to beat Q3 estimates; shares up** Shares of drugmaker Gilead GILD.O rise 5% to $123.58 ** RBC Capital Markets estimates GILD's HIV prevention drug Yeztugo could beat consensus expectations in Q3, projecting sales of $45 million compared to the Street's $35 million, driven by switching demand and early uptake** CVS's decision not to cover Yeztugo yet, along with formulary delays and continued use of generic Truvada, may limit near-term uptake, brokerage adds** RBC Capital Markets expects a Q3 beat for GILD's HIV drug Biktarvy, but continues to monitor for any potential MFN impact longer term** Company is expected to report Q3 earnings on October 30** Including session moves, stock up 33.98% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nL3N3VY18C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","LU1674673428.USD","LU1839511570.USD","IE00BKVL7J92.USD","LU0823416689.USD","SG9999015978.USD","IE00B7SZLL34.SGD","LU1674673691.USD","LU0114720955.EUR","IE00B19Z3581.USD","LU2089984988.USD","BK4566","LU0289739699.SGD","LU0882574055.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","BK4583","LU1066051498.USD","SG9999015952.SGD","LU2468319806.SGD","GILD","LU0320765992.SGD","LU1430594728.SGD","BK4532","SG9999015986.USD","BK4578","BK4568","LU1066053197.SGD","LU0234570918.USD","LU0058720904.USD","BK4585","IE0002270589.USD","LU1778281490.HKD","LU1585245621.USD","BK4139","BK4550","BK4588","LU2324357040.USD","SG9999015945.SGD","LU2087621335.USD"],"gpt_icon":0},{"id":"2576068551","title":"Gilead Sciences Shares Hit All Time High; Last up 4.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576068551","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576068551?lang=en_us&edition=fundamental","pubTime":"2025-10-18 01:30","pubTimestamp":1760722216,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nL3N3VY18K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","LU1674673691.USD","LU0109394709.USD","LU2089984988.USD","LU1066053197.SGD","LU1839511570.USD","SG9999015952.SGD","LU0114720955.EUR","SG9999015986.USD","LU1571399168.USD","LU2468319806.SGD","IE00B3T34201.USD","LU0234570918.USD","LU0320765992.SGD","SG9999015945.SGD","IE0002270589.USD","LU1778281490.HKD","BK4568","IE00B7SZLL34.SGD","LU0289739699.SGD","LU0058720904.USD","BK4585","LU1066051498.USD","LU1585245621.USD","LU0889565916.HKD","BK4532","BK4139","LU2087621335.USD","GILD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU2324357040.USD","LU0823416689.USD","BK4578","IE00BSNM7G36.USD","BK4588","LU0882574055.USD","BK4550","SG9999015978.USD","BK4583","LU1674673428.USD"],"gpt_icon":0},{"id":"2576058366","title":"Novartis Says 5-Year Kisqali Data Cut Early Breast Cancer Recurrence by 28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576058366","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576058366?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:52","pubTimestamp":1760705551,"startTime":"0","endTime":"0","summary":"Novartis  said Friday that five-year results from the phase 3 Natalee study show Kisqali plus endocrine therapy reduced the risk of recurrence by 28% in early HR-positive or HER2-negative breast cancer versus endocrine therapy alone.The combined regimen delivered an 85.5% invasive disease-free survival rate at five years versus 81% for endocrine therapy alone, the company said.Benefit was seen across key subgroups, including patients without lymph-node involvement, Novartis said.Kisqali also showed a 29% reduction in the risk of distant recurrence and a favorable trend in overall survival, though survival data remain immature, the company added.Additionally, the company also said roughly two years after patients finished the three-year Kisqali course, no new safety issues were observed.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0208291251.USD","BK4532","LU0320765489.SGD","BK4585","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4578","IE0002141913.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0070302665.USD","NVS","BK4007","BK4588","LU0211331839.USD"],"gpt_icon":0},{"id":"2576703005","title":"Novartis Says European Regulator Backs Expanded Use of Blood Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2576703005","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576703005?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:46","pubTimestamp":1760705185,"startTime":"0","endTime":"0","summary":"Novartis  said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion on Scemblix for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase across all lines of treatment.The drugmaker said the recommendation was based on results from a phase III trial that demonstrated superior major molecular response rates, fewer dose reductions, and half the rate of treatment discontinuation due to side effects compared with the investigators' choice of tyrosine kinase inhibitor treatment in patients.The European Commission is expected to make a final decision on the CHMP recommendation within two months. If approved, Scemblix will be indicated for both newly diagnosed and previously treated adults, expanding access to four times as many patients in Europe, Novartis said.Scemblix is already approved for earlier-line use in over 20 countries, including the US, Japan, an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0320765489.SGD","IE0009355771.USD","BK4532","IE00BJJMRZ35.SGD","BK4007","LU0070302665.USD","BK4578","IE00B4R5TH58.HKD","NVS","BK4588","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","LU0208291251.USD","IE00BJT1NW94.SGD","IE0002141913.USD"],"gpt_icon":0},{"id":"2576031359","title":"Novartis Scemblix receives positive CHMP opinion for Scemblix","url":"https://stock-news.laohu8.com/highlight/detail?id=2576031359","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576031359?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:55","pubTimestamp":1760698518,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-scemblix-receives-positive-chmp-opinion-for-scemblix-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-scemblix-receives-positive-chmp-opinion-for-scemblix-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","CHMP","IE0009355771.USD","IE0002141913.USD","BK4578","BK4087","LU0070302665.USD","BK4532","LU0211331839.USD","BK4585","LU0320765489.SGD","IE00B4R5TH58.HKD","BK4007","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0208291251.USD","IE00BJT1NW94.SGD","NVS","BK4588"],"gpt_icon":0},{"id":"2576703749","title":"Gilead Sciences Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2576703749","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576703749?lang=en_us&edition=fundamental","pubTime":"2025-10-17 09:29","pubTimestamp":1760664553,"startTime":"0","endTime":"0","summary":"Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL4GX7Jy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","IE0002270589.USD","LU1066053197.SGD","LU0109394709.USD","BK4583","LU1571399168.USD","LU0234570918.USD","LU1066051498.USD","LU0289739699.SGD","LU2089984988.USD","LU1585245621.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU2324357040.USD","LU2087621335.USD","LU1674673428.USD","BK4550","SG9999015986.USD","BK4578","IE00BKVL7J92.USD","LU1674673691.USD","LU0882574055.USD","IE00B7SZLL34.SGD","LU1430594728.SGD","LU2468319806.SGD","IE00B3T34201.USD","LU1778281490.HKD","LU1839511570.USD","LU0058720904.USD","BK4566","LU0114720955.EUR","LU0320765992.SGD","BK4568","IE00BZ1G4Q59.USD","SG9999015945.SGD","IE00B19Z3581.USD","SG9999015978.USD","BK4585","BK4139","SG9999015952.SGD","BK4588","BK4532","GILD","LU0823416689.USD"],"gpt_icon":0},{"id":"2575881748","title":"Novartis' Phase 3 Study of Fabhalta in IgA Nephropathy Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2575881748","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575881748?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:16","pubTimestamp":1760613415,"startTime":"0","endTime":"0","summary":"Novartis  said Thursday that its phase 3 study of Fabhalta in adults with IgA nephropathy kidney disease, or IgAn, met its primary endpoint.The achieved primary endpoint is a \"statistically significant\" improvement in estimated glomerular filtration rate, or eGFR, slope compared with placebo over two years, the company said, noting that eGFR is key marker of kidney function.Another primary endpoint is proteinuria reduction at nine months as measured by UPCR, according to Novartis.Novartis also said Fabhalta was well tolerated during the phase 3 trial, with a safety profile consistent with previously reported data.The company said it plans to use the trial's data to support submissions for Fabhalta in 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFTCPJ56.SGD","IE0002141913.USD","BK4532","LU0208291251.USD","IE00B2B36J28.USD","BK4007","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0070302665.USD","NVS","BK4578","LU0320765489.SGD","LU0211331839.USD","IE0009355771.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2575175217","title":"Novartis announces Phase III study of Fabhalta showed superiority to placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2575175217","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575175217?lang=en_us&edition=fundamental","pubTime":"2025-10-16 18:36","pubTimestamp":1760610966,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta in adults living with IgA nephropathy, Ig...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-phase-iii-study-of-fabhalta-showed-superiority-to-placebo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-phase-iii-study-of-fabhalta-showed-superiority-to-placebo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4585","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","NVS","BK4588","BK4007","IE00B2B36J28.USD","IE0002141913.USD","BK4578","BK4532","LU0070302665.USD","IE00BJJMRZ35.SGD","BK4134","IE0009355771.USD","LU0208291251.USD","III"],"gpt_icon":0},{"id":"2575202415","title":"Gilead presents new HIV research data at European AIDS Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575202415","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575202415?lang=en_us&edition=fundamental","pubTime":"2025-10-15 17:10","pubTimestamp":1760519429,"startTime":"0","endTime":"0","summary":"Gilead (GILD) announced its upcoming participation in the 20th European AIDS Conference to be held in Paris, France from October 15-18. Gilead will...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-presents-new-hiv-research-data-at-european-aids-conference-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-presents-new-hiv-research-data-at-european-aids-conference-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4532","SG9999015986.USD","IE00B3T34201.USD","LU0823416689.USD","LU2087621335.USD","SG9999015952.SGD","IE00BSNM7G36.USD","LU1839511570.USD","LU1066051498.USD","LU2089984988.USD","BK4550","BK4139","LU2468319806.SGD","LU0234570918.USD","IE00B19Z3B42.SGD","BK4578","IE0002270589.USD","LU1674673691.USD","LU2324357040.USD","LU1066053197.SGD","SG9999015978.USD","LU0114720955.EUR","BK4566","LU1430594728.SGD","LU0320765992.SGD","LU0058720904.USD","LU1571399168.USD","LU0889565916.HKD","SG9999015945.SGD","LU0882574055.USD","LU1778281490.HKD","IE00BKVL7J92.USD","LU0109394709.USD","LU1585245621.USD","BK4585","BK4583","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","GILD","LU0289739699.SGD","IE00B19Z3581.USD","LU1674673428.USD","BK4588"],"gpt_icon":0},{"id":"2575204467","title":"Novartis Growth Should Normalize After Successful Turnaround -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2575204467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575204467?lang=en_us&edition=fundamental","pubTime":"2025-10-15 16:59","pubTimestamp":1760518740,"startTime":"0","endTime":"0","summary":"0859 GMT - Novartis completed a successful transformation and now outperforms its peers, but growth is set to normalize, Vontobel's Stefan Schneider writes. The Swiss pharma group's valuation now reflects its recent growth, though this happened more slowly than expected given nine straight quarters of Novartis beating and raising guidance, the analyst says. This is unlikely to be repeated when the company releases third-quarter results later this month, its first report since heart failure drug Entresto lost patent exclusivity, the analysts add. Novartis seems poised to deliver slower growth going forward, the analyst says. Vontobel cuts its recommendation on Novartis stock to hold from buy and keeps its target price of 112 Swiss francs. Shares fall 1.1% to 102.92 francs. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4578","IE00B4R5TH58.HKD","BK4585","BK4532","IE0009355771.USD","LU0070302665.USD","BK4588","LU0211331839.USD","IE00B2B36J28.USD","NVS","LU0208291251.USD","LU0320765489.SGD","BK4007","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2575205932","title":"Gilead Sciences Announces Positive Phase 2 Results for Twice-Yearly Lenacapavir and Advances Long-Acting HIV Prevention and Treatment at EACS 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575205932","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575205932?lang=en_us&edition=fundamental","pubTime":"2025-10-15 15:30","pubTimestamp":1760513419,"startTime":"0","endTime":"0","summary":"Gilead Sciences Announces Positive Phase 2 Results for Twice-Yearly Lenacapavir and Advances Long-Acting HIV Prevention and Treatment at EACS 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire  on October 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL5b02w9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0320765992.SGD","IE00BKVL7J92.USD","LU0109394709.USD","LU2087621335.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","LU1066053197.SGD","LU0234570918.USD","SG9999015945.SGD","BK4578","LU0882574055.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU1839511570.USD","SG9999015986.USD","SG9999015978.USD","BK4550","LU1066051498.USD","LU1585245621.USD","BK4585","SG9999015952.SGD","LU1430594728.SGD","LU0823416689.USD","BK4532","LU2468319806.SGD","BK4588","BK4583","LU0889565916.HKD","IE00B3T34201.USD","LU1571399168.USD","LU2089984988.USD","BK4139","IE00B19Z3B42.SGD","LU2324357040.USD","LU0289739699.SGD","LU1778281490.HKD","BK4566","LU1674673428.USD","LU0058720904.USD","LU1674673691.USD","GILD","BK4568","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2575205536","title":"Gilead Presents New Hiv Research Data at Eacs 2025 – Driving Scientific Innovation in Treatment and Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2575205536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575205536?lang=en_us&edition=fundamental","pubTime":"2025-10-15 15:30","pubTimestamp":1760513400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nTUA8WSRMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0882574055.USD","IE0002270589.USD","LU0109394709.USD","LU1430594728.SGD","BK4578","LU1066051498.USD","LU2324357040.USD","LU1674673428.USD","LU2468319806.SGD","SG9999015945.SGD","IE00B3T34201.USD","LU0234570918.USD","BK4583","IE00BZ1G4Q59.USD","LU2087621335.USD","IE00BKVL7J92.USD","SG9999015952.SGD","GILD","BK4568","LU0823416689.USD","BK4566","BK4532","BK4550","LU0889565916.HKD","LU1585245621.USD","LU1674673691.USD","SG9999015986.USD","BK4585","IE00B7SZLL34.SGD","LU0320765992.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU1571399168.USD","LU2089984988.USD","BK4588","LU0289739699.SGD","SG9999015978.USD","LU1066053197.SGD","LU0114720955.EUR","IE00B19Z3581.USD","LU0058720904.USD","BK4139","LU1778281490.HKD"],"gpt_icon":0},{"id":"2575206406","title":"Gilead Announces Promising Phase 3 Results for Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer and New Data on Domvanalimab Combination in Gastric and Esophageal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575206406","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575206406?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:31","pubTimestamp":1760358673,"startTime":"0","endTime":"0","summary":"Gilead Announces Promising Phase 3 Results for Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer and New Data on Domvanalimab Combination in Gastric and Esophageal Cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire  on October 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL4dHHk3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","IE00B3T34201.USD","LU0109394709.USD","LU1674673691.USD","LU0058720904.USD","RCUS","LU0882574055.USD","SG9999015952.SGD","BK4566","IE00BSNM7G36.USD","IE0002270589.USD","BK4568","LU1674673428.USD","LU2324357040.USD","GILD","IE00B19Z3B42.SGD","BK4550","IE00BZ1G4Q59.USD","LU1839511570.USD","SG9999015945.SGD","BK4532","LU1778281490.HKD","LU2089984988.USD","LU0320765992.SGD","IE00B7SZLL34.SGD","BK4585","IE00BKVL7J92.USD","LU0234570918.USD","LU2087621335.USD","SG9999015978.USD","SG9999015986.USD","BK4583","BK4578","LU1585245621.USD","LU0889565916.HKD","LU1066053197.SGD","LU2468319806.SGD","IE00B19Z3581.USD","LU0823416689.USD","BK4139","BK4588","LU1430594728.SGD","LU1571399168.USD","LU0114720955.EUR","LU0289739699.SGD"],"gpt_icon":0},{"id":"2575406466","title":"Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at Esmo 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575406466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575406466?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:30","pubTimestamp":1760358600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA76XW4P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","IE00BZ1G4Q59.USD","LU0320765992.SGD","BK4568","BK4550","LU1066051498.USD","LU1674673691.USD","IE00B19Z3581.USD","LU0289739699.SGD","BK4532","BK4585","LU2324357040.USD","LU2087621335.USD","LU0882574055.USD","LU0058720904.USD","IE00BSNM7G36.USD","BK4578","LU1674673428.USD","LU1585245621.USD","IE00B3T34201.USD","IE0002270589.USD","SG9999015986.USD","LU1839511570.USD","SG9999015978.USD","IE00B7SZLL34.SGD","LU1571399168.USD","BK4583","BK4139","GILD","LU0114720955.EUR","LU2468319806.SGD","IE00B19Z3B42.SGD","LU2089984988.USD","LU0889565916.HKD","SG9999015952.SGD","LU1066053197.SGD","SG9999015945.SGD","LU0823416689.USD","BK4588","IE00BKVL7J92.USD","LU1778281490.HKD","LU0109394709.USD","LU0234570918.USD","BK4566"],"gpt_icon":0},{"id":"2575405074","title":"Novartis Growth Likely to Stall on Cosentyx Sales Slide -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2575405074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575405074?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:11","pubTimestamp":1760357460,"startTime":"0","endTime":"0","summary":"1206 GMT - Novartis's earnings growth will stall in 2026 due to larger-than-expected losses from slowing sales of its Cosentyx autoimmune treatment, Intron Health analysts write. Cosentyx U.S. sales are likely to drop 17% mainly due to increased competition and lower prices and compared with consensus forecasts for a 10% rise, the analysts say. The decrease could cut Novartis's EBIT by about 5%, they add. Together with the Swiss pharma group's Entresto heart-failure drug loss of patent exclusivity, this will likely lead to flat earnings per share next year, the analysts write. Moreover, Novartis's long-term revenue growth remains weak and lags that of other major European drugmakers, the analysts add. Intron Health cuts its recommendation on Novartis's stock to hold from buy. Shares fall 0.4% Monday and are up 18% year to date. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","IE00BJJMRZ35.SGD","BK4007","IE0009355771.USD","NVS","LU0211331839.USD","BK4588","IE00BJT1NW94.SGD","BK4585","IE0002141913.USD","LU0320765489.SGD","BK4532","BK4578","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0070302665.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2574292199","title":"Press Release: Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2574292199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574292199?lang=en_us&edition=fundamental","pubTime":"2025-10-10 04:08","pubTimestamp":1760040480,"startTime":"0","endTime":"0","summary":"Gilead Sciences, Inc.  announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2025 financial results and provide a business update.A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.For more information on Gilead Sciences, please visit the company's website at www.gilead","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0109394709.USD","SG9999015978.USD","IE00B19Z3581.USD","BK4532","LU1674673691.USD","BK4585","SG9999015952.SGD","LU0058720904.USD","LU0234570918.USD","LU0320765992.SGD","BK4508","LU0882574055.USD","LU1430594728.SGD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","LU0114720955.EUR","LU2324357040.USD","SG9999015986.USD","BK4583","BK4578","LU0823416689.USD","LU1585245621.USD","SG9999015945.SGD","BK4139","LU1571399168.USD","LU2087621335.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","BK4077","IE00BZ1G4Q59.USD","LU0889565916.HKD","GILD","BK4534","TWTR","LU1674673428.USD","IE0002270589.USD","LU1066053197.SGD","BK4566","LU2468319806.SGD","BK4550","LU2089984988.USD","BK4568","BK4588","IE00BSNM7G36.USD","IE00B3T34201.USD","LU1066051498.USD","LU1839511570.USD","BK4579","LU0289739699.SGD"],"gpt_icon":0},{"id":"2573264941","title":"Gilead : Citigroup Raises Target Price to $135 From $125","url":"https://stock-news.laohu8.com/highlight/detail?id=2573264941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573264941?lang=en_us&edition=fundamental","pubTime":"2025-10-08 17:53","pubTimestamp":1759917226,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VP1FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","LU0320765992.SGD","IE00B3T34201.USD","GILD","LU0109394709.USD","BK4568","BK4578","LU1674673691.USD","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4566","LU0823416689.USD","IE00BSNM7G36.USD","BK4583","BK4139","LU1066051498.USD","LU2468319806.SGD","SG9999015986.USD","LU0058720904.USD","LU0882574055.USD","LU1674673428.USD","LU2324357040.USD","LU2089984988.USD","LU1839511570.USD","SG9999015945.SGD","BK4585","SG9999015952.SGD","LU1585245621.USD","IE00B19Z3581.USD","LU1571399168.USD","IE00B19Z3B42.SGD","IE0002270589.USD","LU1778281490.HKD","BK4588","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU2087621335.USD","BK4550","SG9999015978.USD","LU1430594728.SGD","IE00BKVL7J92.USD","LU0114720955.EUR","LU0234570918.USD"],"gpt_icon":0},{"id":"2573515944","title":"Gilead price target raised to $135 from $125 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2573515944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573515944?lang=en_us&edition=fundamental","pubTime":"2025-10-08 17:50","pubTimestamp":1759917008,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham raised the firm’s price target on Gilead (GILD) to $135 from $125 and keeps a Buy rating on the shares. Citi’s survey of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-135-from-125-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-135-from-125-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0234570918.USD","IE00B19Z3581.USD","LU1778281490.HKD","BK4532","LU1430594728.SGD","LU2089984988.USD","LU0823416689.USD","BK4585","LU1839511570.USD","SG9999015978.USD","BK4578","LU2324357040.USD","LU1674673691.USD","BK4568","LU0882574055.USD","SG9999015952.SGD","BK4583","LU1674673428.USD","BK4550","IE0002270589.USD","LU2087621335.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE00BKVL7J92.USD","LU2468319806.SGD","LU0058720904.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU1066053197.SGD","LU0114720955.EUR","LU0109394709.USD","BK4588","IE00B3T34201.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","BK4139","IE00B7SZLL34.SGD","LU1571399168.USD","SG9999015945.SGD","GILD","BK4566","SG9999015986.USD"],"gpt_icon":0},{"id":"2573141914","title":"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Veeva Systems (VEEV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573141914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573141914?lang=en_us&edition=fundamental","pubTime":"2025-10-08 13:20","pubTimestamp":1759900805,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report) and Veeva...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-veeva-systems-veev-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-veeva-systems-veev-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","LU0170899867.USD","BK4581","XBI","BK4167","LU2324357040.USD","SG9999015945.SGD","BK4528","BK4137","VEEV","LU1571399168.USD","LU0823416689.USD","LU1989764664.SGD","IE00B7SZLL34.SGD","BK4566","BK4585","IE00B19Z3581.USD","SG9999015986.USD","LU1839511570.USD","GILD","BK4139","LU1778281490.HKD","BK4578","BK4588","LU0289739699.SGD","LU0234570918.USD","IE00BSNM7G36.USD","LU0320765992.SGD","SG9999015978.USD","LABU","LU0109394709.USD","LU0266013472.USD","HCSG","LU1674673428.USD","LU1674673691.USD","LU2089984988.USD","LU0114720955.EUR","IE0002270589.USD","IE00B3T34201.USD","LU1066053197.SGD","LU1430594728.SGD","BK4550","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","XLV","BK4613","LU2087621335.USD","BK4568","BK4504"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}